Molecular Glue Degrader Patents: Who Leads, Where the Gaps Are 2026
Molecular Glue Degrader Discovery Patents
34.7% concentration at the top. The five leading assignees hold 150 of 432 records in scope — a tight cluster followed by a long tail of single- and few-filing entrants. Filings started from zero in 2017, built steadily, and peaked at 93 records in 2023. The 2021-to-2024 window shows 82% growth in annual volume — the clearest complete-year signal in the dataset. Treat 2025 and 2026 counts as provisional given the typical 18-month publication lag.
- 1GLUETACS THERAPEUTICS (SHANGHAI) CO LTD40
- 2THE BRIGHAM & WOMEN S HOSPITAL INC33
- 3ST JUDE CHILDRENS RES HOSPITAL INC30
- 4THE BROAD INST INC26
- 5C4 THERAPEUTICS INC21
See the full molecular glue degrader discovery analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about molecular glue degrader patents
How many patent families exist for molecular glue degraders?
This dataset identifies 432 published records in scope, filed or published between 2015 and mid-2026, using search terms covering molecular glue chemistry, cereblon binding, ternary complex formation and related discovery methods. The assignee ranking built from these records covers 97 companies. Because a single invention can generate several related filings across jurisdictions, patent families are a more reliable unit for counting distinct inventions than raw document counts, though the 432 figure already reflects family-level counting in this ranking.
Who are the leading companies filing molecular glue degrader patents?
The field shows a concentrated top tier: the leading assignee holds 40 of the 432 records, and the top five combined account for 150 records, or 34.7% of all records in scope. The top ten extend that to 55.6%. Beyond that group, the remaining 87 ranked companies each hold comparatively small counts, forming a long tail typical of a research area still moving from academic discovery into company-led platforms.
Is molecular glue degrader patent filing still growing?
Yes, based on the complete-year data. Filings rose from 45 records in 2021 to 82 in 2024, an 82% increase, and 2023 was the single busiest year so far with 93 records. The lower counts shown for 2025 and 2026 reflect the roughly 18-month lag between filing and publication rather than an actual slowdown, so those most recent years should not be read as a decline.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Molecular Glue Degrader Discovery covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.